Immunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of “Buy” by Brokerages

Immunic, Inc. (NASDAQ:IMUX) has earned an average rating of “Buy” from the eight research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $7.40.

A number of equities analysts recently commented on IMUX shares. D. Boral Capital reiterated a “buy” rating and set a $8.00 price objective on shares of Immunic in a research report on Wednesday, January 7th. Roth Mkm began coverage on Immunic in a research note on Friday, November 7th. They issued a “buy” rating and a $3.00 target price for the company. LADENBURG THALM/SH SH upgraded Immunic to a “strong-buy” rating in a report on Thursday, October 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunic in a report on Monday, December 29th. Finally, HC Wainwright cut their price objective on shares of Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 14th.

Institutional Trading of Immunic

Several institutional investors have recently made changes to their positions in IMUX. Qube Research & Technologies Ltd purchased a new position in Immunic in the third quarter worth approximately $29,000. Millennium Management LLC lifted its stake in shares of Immunic by 414.5% in the 3rd quarter. Millennium Management LLC now owns 530,470 shares of the company’s stock valued at $468,000 after purchasing an additional 427,361 shares during the last quarter. Focus Partners Wealth lifted its stake in shares of Immunic by 1.5% in the 3rd quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock valued at $2,276,000 after purchasing an additional 39,063 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Immunic during the 3rd quarter worth $99,000. Finally, Two Sigma Investments LP acquired a new stake in shares of Immunic during the 3rd quarter worth about $52,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Stock Up 2.5%

Shares of NASDAQ IMUX opened at $0.63 on Friday. The firm has a 50-day simple moving average of $0.63 and a 200-day simple moving average of $0.78. The stock has a market capitalization of $75.18 million, a price-to-earnings ratio of -0.75 and a beta of 1.54. Immunic has a 52 week low of $0.51 and a 52 week high of $1.39.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.05. As a group, equities research analysts expect that Immunic will post -0.94 EPS for the current year.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.